Speaker Profile

Ph.D., Co-founder and CEO, Strata Oncology

Biography
Dan Rhodes is a scientist and entrepreneur focused on precision medicine in oncology. He co-founded Strata Oncology, a venture-backed precision oncology company committed to acceler-ating the impact of precision medicine for patients with cancer. Previously, Dan was VP of Oncology for Thermo Fisher Scientific (Life Technologies) where he oversaw the development of cancer sequencing products and pharma companion diagnostic partnerships. Prior to that, Dan was co-founder and CEO of Compendia Bioscience, a University of Michigan spin-off formed to commercialize his thesis project, Oncomine, a cancer genome data-mining platform. Dan has co-authored 40+ publications and is a co-inventor on 10 patents, including the discov-ery of gene fusions as a genetic cause of prostate cancer. In 2019, Dan was named Ernst & Young Entrepreneur of the Year for the Midwest region. Dan served on the oversight committee for the Michigan Translational Research and Commercialization (MTRAC) Program and on multi-ple advisory boards.


 Session Abstract – PMWC 2022 Silicon Valley

Track 3, June 28


Precision medicine is among the key contributors in progressing cancer survivorship. However, biomarker testing, which is critical to enabling precision medicine treatments, is below guideline recommendations due to various factors. The session will discuss these barriers, as well as bringing tangible and sustainable solutions to patients with cancer through collaboration.

 Session Abstract – PMWC 2022 Silicon Valley

Track 3, June 28


  • Dismantling Barriers to Biomarker Testing Through Collaboration (PANEL)
    Session Chair: Omar Perez, AstraZeneca
    - Nikki Martin, LUNGevity
    - Laura J. van ’t Veer, UCSF
    - Jenn Higgins, Guardant Health
    - Dan Rhodes, Strata Oncology
  • Health Systems Perspective: Leveraging Real-world Evidence to Improve Patient Care (PANEL)
    Session Chair: Anna Berry, Syapse
    - Mary Walters, Aurora Health
    - Haythem Y Ali, Henry Ford Health System
  • Comprehensive Profiling: Combination of Tissue and Plasma Biomarker Strategies
    Session Chair: Maggie Rougier-Chapman, Personal Genome Diagnostics (PGDx)
    - Cynthia Pointer, Genapsys
    - Ravi Kolhe, Augusta University
    - Stephen Miller, Blueprint Medicines
  • Immuno-oncology Biomarkers for Predicting Drug Efficacy
    Session Chair: Ronnie Andrews, Oncocyte
    - Paul Billings, Biological Dynamics
    - Daniel Rhodes, Strata Oncology
  • Reimagining Oncology - Closing the Gaps between Science and Clinic (PANEL)
    Session Chair: Christian Wolfrum, Siemens Healthineers
    - Ben Gonzales, Biognosys AG
    - Debanti Sengupta, Varian
    - Rangarajan Sampath, Siemens Healthineers
    - Isma Benattia, Amgen
  • Challenges to Implementing Precision Medicine in the Community Setting (PANEL)
    Session Chair: Jerry Mitchell, Foundation Medicine
    - Erika Brown, One Cancer Place
    - Vivian Lee, Patient Advocate
    - Kashyap Patel, Community Oncology Alliance
    - Christopher Woods, Sutter Health
  • Combined Utilization of Precision Medicine Technologies in Primary Clinics
    - Gad Rennert, Carmel Medical Center
  • PMWC Showcase
    - Paul Dempsey, Hawkeye Bio, Inc.